| Name | Title | Contact Details |
|---|
The Kentucky Association of Health Care Facilities/Kentucky Center for Assisted Living (KAHCF/KCAL) is the trade association that represents propriety and non-proprietary nursing facilities, personal care homes, and assisted living communities across the Commonwealth. One of the state affiliates of the American Health Care Association/National Center for Assisted Living (AHCA/NCAL), KAHCF/KCAL provides a wide variety of services to member facilities including legislative and regulatory activities, professional development, statewide recognition programs, publications, media relations, research and advocacy relations.
United American Healthcare Corporation is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At Roche Diagnostics, our focus is to improve the lives of patients, from research to lab tests to personalized healthcare; we touch the entire spectrum of diagnostics users. Roche Diagnostics is a member of the Roche Group, which is headquartered in Basel, Switzerland. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world`s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche`s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Roche has over 90,000 employees worldwide and invested over 9 billion Swiss francs in R&D. Roche Diagnostics` North American headquarters, located in Indianapolis, has about 4,200 employees and is home to U.S. research and development, laboratory, manufacturing, distribution, information technology and administrative operations.
CliniQAl Consult Corporation is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic